ALZAI Health has reported the validation of its AI-driven Alzheimer’s disease risk identification models using data from more than 1.1 million patients in the US.
The company reported that its risk-stratification models achieved performance comparable to earlier validations that used Israeli healthcare data.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The validation project used a longitudinal healthcare dataset licensed from HealthVerity, which included approximately 38 million common blood chemistry lab test results and more than three million chronic disease diagnostic records, spanning over 100 million clinical data points.
This dataset consisted of real-world data collected through routine care and was not influenced by HealthVerity in terms of model development, validation methodology, or result analysis.
HealthVerity did not participate in drawing conclusions or verifying the outcomes.
The validation evaluated Alzai Health’s AI solution over multiple prediction horizons and with varying patient history durations.
Models were tested using blood test data only, chronic disease diagnoses only, and a combination of both data types.
Alzai Health’s technology is based on widely available clinical information and basic patient demographics, and it is designed to offer a population-level risk screening tool.
The results indicate that the company’s technology may function consistently across different healthcare systems and patient populations.
The findings were based on a licensed retrospective dataset and specific model methodologies, cautioning that results may not be replicated in prospective studies, other datasets, or wider clinical implementation.
Alzai Health considers this validation an important step towards potential commercialisation in the US market.
The company stated that consistent performance across independent healthcare datasets could support broader applicability of its technology in US healthcare environments, pharmaceutical research, and population health programmes.
The technology is intended for Alzheimer’s disease risk identification and is not designed to diagnose the condition or substitute clinical judgement.
Alzai Health CEO Hayim Raclaw said: “Alzheimer’s has been a rapidly growing problem, and this healthcare reality is compounded by the fact that the vast majority of patients are diagnosed too late for the most effective treatments, and most people at elevated risk remain unidentified for preventative care.
“Validating our technology using a large-scale, real-world US healthcare data represents an important milestone for Alzai and further demonstrates the robustness and scalability of our non-invasive disease risk screening solution.”
